Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 4Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Thoracic 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Metastatic Adenocarcinoma of the Pancreas 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 30Cisplatin 20Carboplatin 20Paclitaxel 18Dexamethasone 15Pemetrexed 13Nivolumab 13Ipilimumab 12Fluorouracil 11Cyclophosphamide 11Gemcitabine 10Trastuzumab 9Docetaxel 9Cytarabine 9daratumumab 8atezolizumab 8Rituximab 8Capecitabine 8Lenalidomide 7Doxorubicin 7zanubrutinib 6Prednisone 6Daunorubicin 6Bortezomib 6venetoclax 5trametinib 5nilotinib 5ibrutinib 5fludarabine 5dabrafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has announcements × Albumin-Bound Paclitaxel × Clear all
NCT04083235 2026-04-20

NAPOLI 3

Ipsen

Phase 3 Completed
770 enrolled 13 charts 1 FDA
Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

NCT02819518 2024-11-27

KEYNOTE-355

Merck Sharp & Dohme LLC

Phase 3 Completed
882 enrolled 41 charts 1 FDA
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02775435 2024-10-08

KEYNOTE-407

Merck Sharp & Dohme LLC

Phase 3 Completed
559 enrolled 18 charts 1 FDA
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02425891 2022-07-19

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Hoffmann-La Roche

Phase 3 Completed
902 enrolled 27 charts 1 FDA
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡